Samantha Semenkow
Stock Analyst at Citigroup
(2.25)
# 2,821
Out of 5,182 analysts
78
Total ratings
40.91%
Success rate
-1.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Buy | $14 → $17 | $9.80 | +73.47% | 3 | Apr 2, 2026 | |
| BEAM Beam Therapeutics | Maintains: Buy | $64 → $68 | $24.66 | +175.75% | 4 | Mar 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $131 → $142 | $86.29 | +64.56% | 3 | Mar 20, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $102 → $123 | $76.99 | +59.76% | 2 | Mar 16, 2026 | |
| BIOA BioAge Labs | Maintains: Buy | $15 → $52 | $17.50 | +197.14% | 6 | Mar 10, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $38 → $46 | $35.20 | +30.68% | 2 | Mar 5, 2026 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $33 → $35 | $24.69 | +41.76% | 4 | Mar 3, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $12 → $14 | $4.79 | +192.28% | 7 | Feb 25, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $33 | $14.43 | +128.69% | 1 | Feb 17, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $26 → $35 | $28.33 | +23.54% | 4 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,124 → $1,091 | $746.75 | +46.10% | 8 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $15 | $14.44 | +0.42% | 2 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $64 | $47.58 | +34.51% | 1 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $30 | $7.28 | +312.09% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $100 | $53.48 | +86.99% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4.25 | $3.32 | +28.01% | 5 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $17.36 | -71.20% | 3 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $2.96 | +237.84% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.48 | +61.29% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.96 | +203.03% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $15 | $3.20 | +368.75% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $80 | $31.02 | +157.90% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $2.67 | +461.80% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $24.50 | +104.08% | 3 | Sep 27, 2023 |
Biohaven
Apr 2, 2026
Maintains: Buy
Price Target: $14 → $17
Current: $9.80
Upside: +73.47%
Beam Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $64 → $68
Current: $24.66
Upside: +175.75%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Buy
Price Target: $131 → $142
Current: $86.29
Upside: +64.56%
Nektar Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $102 → $123
Current: $76.99
Upside: +59.76%
BioAge Labs
Mar 10, 2026
Maintains: Buy
Price Target: $15 → $52
Current: $17.50
Upside: +197.14%
Agios Pharmaceuticals
Mar 5, 2026
Maintains: Buy
Price Target: $38 → $46
Current: $35.20
Upside: +30.68%
Catalyst Pharmaceuticals
Mar 3, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $24.69
Upside: +41.76%
Larimar Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $4.79
Upside: +192.28%
Cullinan Therapeutics
Feb 17, 2026
Initiates: Buy
Price Target: $33
Current: $14.43
Upside: +128.69%
Roivant Sciences
Feb 10, 2026
Maintains: Buy
Price Target: $26 → $35
Current: $28.33
Upside: +23.54%
Jan 8, 2026
Maintains: Buy
Price Target: $1,124 → $1,091
Current: $746.75
Upside: +46.10%
Dec 22, 2025
Downgrades: Neutral
Price Target: $17 → $15
Current: $14.44
Upside: +0.42%
Dec 17, 2025
Initiates: Buy
Price Target: $64
Current: $47.58
Upside: +34.51%
Dec 9, 2025
Maintains: Buy
Price Target: $16 → $30
Current: $7.28
Upside: +312.09%
Dec 9, 2025
Maintains: Buy
Price Target: $60 → $100
Current: $53.48
Upside: +86.99%
Nov 11, 2025
Maintains: Neutral
Price Target: $5 → $4.25
Current: $3.32
Upside: +28.01%
Oct 29, 2025
Downgrades: Sell
Price Target: $5
Current: $17.36
Upside: -71.20%
Aug 14, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $2.96
Upside: +237.84%
May 15, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $2.48
Upside: +61.29%
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $3.96
Upside: +203.03%
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $3.20
Upside: +368.75%
Jun 3, 2024
Reinstates: Buy
Price Target: $80
Current: $31.02
Upside: +157.90%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.67
Upside: +461.80%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $24.50
Upside: +104.08%